RxDoctor Payments Data

Melissa Welch

Nurse Practitioner · Cumberland, MDNPI 1477798817

Payments from drug & device makers

$1,633in general payments, 2019–2025

Across 63 payments — averaging $25.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$673
  • Novo Nordisk$349
  • AbbVie$139
  • GSK$88
  • Pfizer$83
  • Lilly USA, LLC$66
  • plus $235 from 9 others

What the payments were for

  • Food & beverage$1,633100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,633 in reported general payments places this provider in the 85th percentile of 1,562 nurse practitioner providers in Maryland.

See all nurse practitioner providers in Maryland

Medicare billing

Part B allowed, 2024
$26,318
Medicare patients
20
Services billed
278

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala30$135,618
OzempicSemaglutide105$124,127
MounjaroTirzepatide40$41,680
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl243$21,911
JardianceEmpagliflozin16$15,916
TrulicityDulaglutide13$15,487
FarxigaDapagliflozin Propanediol12$14,438
TradjentaLinagliptin12$11,976
Advair HfaFluticasone Propion/Salmeterol13$11,454
SuboxoneBuprenorphine Hcl/Naloxone Hcl27$9,237
Breo ElliptaFluticasone/Vilanterol15$6,051
ZubsolvBuprenorphine Hcl/Naloxone Hcl16$5,347
Lantus SolostarInsulin Glargine,hum.Rec.Anlog31$4,961
ShingrixVaricella-Zoster Ge/As01b/Pf16$3,300
Albuterol Sulfate HfaAlbuterol Sulfate99$2,652

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy$673$135,61830 claims
Novo NordiskOzempic$349$124,127105 claims
Lilly USA, LLCMounjaro, Trulicity$66$57,16853 claims
AstraZenecaFarxiga$48$14,43812 claims
GSKBreo Ellipta, Shingrix$88$9,35131 claims
Indivior Inc.Suboxone$38$9,23727 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,562 nurse practitioner providers in Maryland.

Other nurse practitioner in Cumberland

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →